학술논문

Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2019, 37 15, 1p. Supplement: S
Subject
Language
English
ISSN
15277755